P16INK4A expression and HPV-L1 detection in the uterine cervix: cyto-histological and immunoistochemical study M.A. Caponio, T. Addati, G. Giannone, *G.

Slides:

Advertisements

Similar presentations

CHROMOSOME 17 POLYSOMY ON HER2/Neu STATUS IN BREAST CANCER

Advertisements

Clinical Performance of the APTIMA HPV Assay for Detection of E6/E7 mRNA from High-Risk HPV Types in Liquid Based Cytology Specimens C. Hill1, J. Dockter1,

Cervical Screening Guidelines - for now and the future - Meg McLachlin, MD, FRCPC.

Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University.

MANAGEMENT OF THE ABNORMAL PAP SMEAR

Updates on Pap Smear Guidelines 2014

Evolution of Neoplasia The Uterine Cervix As a Model Raj C. Dash, MD Duke University Medical Center Durham, North Carolina.

ASHLYN SAVAGE, MD, MSCR ASSOCIATE PROFESSOR OBSTETRICS AND GYNECOLOGY MEDICAL UNIVERSITY OF SOUTH CAROLINA Managing Abnormal Pap Smears: Incorporating.

Comparison of HPV Testing and Spectroscopy Combined with Cytology for the Detection of High- grade Cervical Neoplasia C Werner, W Griffith III, R Ashfaq,D.

COLPOSCOPY RANDOM CERVICAL BIOPSIES ENDOCERVICAL CURETTAGE S.C.P.M.G.-Fontana.

Cervix Dr. Raid Jastania. Cervical Cancer Screening HPV infection Pre- Cancerous Dysplasia Cancer years.

Screening for Cervical Cancer

Management of Women with CIN 1 or LSIL

HUMAN PAPILLOMA VIRUS and CERVICAL CARCINOMA Roger J Rand.

Benign and premalignant disease of the cervix

Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,

Clinical Uses of HPV DNA Testing

IMMUNOCYTOCHEMICAL AND MOLECULAR HELP IN THYROID LIQUID BASED CYTOLOGY. G. Simone, M. Liuzzi, G. Achille, S. Russo, F. Palma, G. Giannone, V. Rubini, C.

Cervical Cancer Screening

Screening in Developed Countries Lynette Denny Gynaecology Oncology Unit Department Obstetrics & Gynaecology and Institute Infectious Diseases and Molecular.

Bayesian Modelling for Clinical Decision Support: Cervical Cancer Screening1/31 University of Pittsburgh Medical Center (UPMC) Magee-Womens Hospital (MWH)

Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.

STUDY OF MULTIMODAL HYPERSPECTROSCOPY IN A POPULATION OF WOMEN AT RISK FOR CERVICAL CANCER Olutosin Awolude α, Brenda Shultz β, Babatunde Akinwunmi α,

H UMAN PAPILLOMAVIRUS AND BREAST CANCER Giles Davies An update on research progress.

Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.

SoftPAP® A Novel Collection Device for Cervical Cytology.

Screening for cervical cancer. Screening for cervical lesions Common disease Cancer is preventable Screening is easy MUST BE PERFORMED.

Current guidelines for Cervical Cancer Screening

In the Name of God. Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University.

International Scientific Congress for Students, Young Physicians and Pharmacists Marisiensis 2014.

David Y. Zhang MD, PhD, MPH Professor Director, Molecular Pathology Departments of Pathology Icahn School of Medicine at Mount Sinai, New York Molecular.

Cervical Intraepithelial Neoplasm

KATIE OSTROM PAPS, ABORTION, AND VACUUM DELIVERY.

Liver Fine needle aspiration using Liquid Based Cytology G Simone, M Asselti, G Caldarola-Gadaleta, T Addati, G Giannone, M Liuzzi, F Palma, V Rubini,

Top Pap smear Questions. 1-When should Pap screening begin? Age 21 y/o,3yrs after first intercourse.

HspE7 INFECTIOUS DISEASE VACCINE FOR THE TREATMENT OF CERVICAL CARCINOMA.

A non-enveloped DNA virus which infects the skin/ mucous membranes of humans.

Sarah Feldman MD MPH Co-Director Ambulatory Gynecologic Oncology Brigham & Women’s Hospital Dana Farber Cancer Institute Lowell Cancer Center Associate.

Cytologic Findings in Type 2 Cervical Carcinomas: Some Cervical Carcinomas are more Difficult to Prevent with Screening R. Marshall Austin MD,PhD Magee-Womens.

Premalignant lesions of the cervix. Applied anatomy.

2006 ASCCP Consensus Guidelines Anne L. Kittendorf, MD FAAFP Assistant Professor University of Michigan Department of Family Medicine.

Joana Ribeiro BSc in Clinical Analysis and Public Health MSc in Medicine and Molecular Oncology PhD student in Biomedical Sciences _________________________________.

Discovery of Novel Methylated Genes in Cervical Carcinogenesis: Methylation of GREM1 and NID2 is Detected in the Majority of Invasive Cervical Cancers.

HIV Infection Increases Risk of ASCUS and Subsequent Development of SILs Slideset on: Duerr A, Paramsothy P, Jamieson DJ, et al. Effect of HIV infection.

Cytopathology Feb

Morphologic Pap Test Findings in HPV Negative Women Age 30 Years and Older: What Information Will Be Lost with HPV Only Primary Screening? Brooke Henninger,

New Technologies in cervical cancer screening Cosette Wheeler, University of New Mexico Albuquerque, New Mexico.

Cervical Cancer Screening NURS 541: Women’s Healthcare – Diagnosis and Management.

Contact: PRELIMINARY RESULTS OF FIRST HPV PRIMARY SCREENING PRIVATE SECTOR IN BUENOS AIRES FEMALE POPULATION R. Jiménez del Toro,

Fig. 1. Framework of developing a guideline for cervical cancer screening. ① Benefits of pap test screening, ② harms of pap test screening, ③ accuracy.

Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions ELINA VIRTANEN1, ILKKA KALLIALA2,3,

Concentration Levels of IL -10 and TNF-α Cytokines in Patients with HPV DNA Positive and Negative Cervical Lesions* Katan Sabir Ali *, Husham Y.

No conflicts of interest

Cervical Cancer Colposcopy & Treatment

From: Inefficiencies and High-Value Improvements in U. S

Various types of cervical lesions as seen on Pap smears:

Risk factors for cervical intraepithelial neoplasia recurrence after loop electrosurgical excision procedure in HIV-1-infected and non-infected women.

Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia A. Gradíssimo Oliveira, C. Delgado,

Disagreement in high-grade/low-grade intraepithelial neoplasia and high-risk/low-risk HPV infection: clinical implications for anal cancer precursor lesions.

Mannose-Binding Lectin Does Not Act as a Biomarker for the Progression of Preinvasive Lesions of Invasive Cervical Cancer Med Princ Pract - DOI: /

Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia A. Gradíssimo Oliveira, C. Delgado,

Primary HPV test screening

Neoplasia of the cervix

SH-sheikhhasani Gyn-oncologist

HUMAN PAPILLOMA VIRUS and CERVICAL CARCINOMA

The 7th EAHSC Detection of human papillomavirus DNA in tumors from Rwandese breast cancer patients Dr. Habyarimana T1,2,3, Attaleb M1, Mazarati JB3, Bakri.

Fig. 2. Three cervical screening strategies to detect CIN2+/CIN3+

Fig. 1. Flowchart of inclusion and exclusion criteria of the study population.ASC-US, atypical squamous cells of undetermined significance; CIN, cervical.

Cumulative probability of CIN2 stratified by HPV test results.

Presentation transcript:

p16INK4A expression and HPV-L1 detection in the uterine cervix: cyto-histological and immunoistochemical study M.A. Caponio, T. Addati, G. Giannone, *G. Falco, A. Labriola, S. Petroni, V. Rubini, G. Simone UOC ANATOMIA PATOLOGICA *UOC GINECOLOGIA IRCCS – Istituto Tumori “Giovanni Paolo II”

OBJECT: The most important event in carcinogenesis of the cervical cancer (CC) is the infection by HPV and the viral integration in cellular DNA. The “progression timing“ between the developement of the lesion in CC after viral integration is unknown. P16INK4A protein is tightly correlated to expression of HPV-L1 protein.

Mechanism of p 16INK4a over-expression

METHODS 137 women underwent Pap Test using LBC. 78 cases had the corresponding bioptic/surgical sample. 40 cases were analised for HPV-L1 protein expression both in LBC and in the corresponding tissue sample. AIM The prevalence of the lesions, the cyto-histological correlation, the presence of HPV and the incidence of p16 (score 0 to 4), were observed.

RESULTS (1) In none of the 35 evaluated cases with Negative cytology, (including 6 HPV+) and in 18 ASCUS, p16 immunoreactivity (IR) has been evidenced. IR has been found in 1/4 cases AGUS, in 4/20 L-SIL, in 6/11 H-SIL and in 2/4 SCC.

RESULTS (2) In 51/78 cases, in which the histological sample was available, the p16 IR has been determined: a strong IR was present in 1/28 negative cases, 2/8 lesions CIN1, 9/12 CIN2-3, 3/3 SCC. In the evaluable cases (excluding ASCUS, AGUS and L-SIL) the Overall Agreement was 91% (83.3% with LSIL).

RESULTS (3) In 18 evaluable cases, p16 has been determined both on the cytological and histological samples: in 2 cases* IR was present only on the cytological sample, while in 1 case** the opposite event was observed.

RESULTS (4) In 75 cases the presence of HPV has been determined: 15 case p16 IR positive also presented infection by LR-HR HPV; in 21/44 cases that didn't express p16 IR, LR-HR HPV infection was detected.

HPV-L1 P 16 In 40 cases, analised for HPV-L1 expression, we observed the different localization in 1 case L1+/P16+ in HSIL.

HPV-L1 1 case L1+/P16+ in HSIL Cyto-histological HPV-L1 detection

P 16 P16 detection in basal layer

Cytologycal L1+/P16- in H-SIL P 16 HPV-L1

CONCLUSIONS: Our study shows that the presence of p16 and HPV-L1 protein in cyto-histological samples could be useful in giving information on viral integration and lesions progression.